Ensoma
Albert Seymour has spent more than 20 years coupling the discipline of human genetics with pharmaceutical R&D, resulting in the delivery of multiple therapeutic programs into development. As chief scientific officer of Homology Medicines, Albert is responsible for translating the company’s dual in vivo gene therapy and gene editing platform into treatments for rare genetic disorders, including advancing the world’s first gene therapy clinical trial for phenylketonuria in just under three years.
This person is not in the org chart
This person is not in any offices
Ensoma
1 followers
Ensoma believes every person, no matter where they are, should have access to innovative technologies that are changing the way we treat disease. Harnessing the power of their Engenious™ vectors, their therapies can be delivered in a simple, single injection.